ESR1 and neoplasm: An early peak, occurring in the first 18 postoperative months, has been observed repeatedly in breast cancer patients [28–30] with particular relevance in patients with large tumor size, high histological grade, lymph node involvement or low expression of estrogen receptors [12, 31].